Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATB1091
- Development stage
- Preclinical
- Lead developer
- Amtix Bio
- Modality
- Small Molecules
01
Overview
ATB1091 is a small molecule drug candidate under development by AmtixBio for the treatment of pain. It is developed using AmtixBio's proprietary FADeR (Functionalized Amino acid Derivatives Repository) platform, which focuses on functionalized amino acid derivative-based small molecules. While some English-translated pipeline materials from the company list the indication as 'Paregoric' (a historical term for an anodyne or pain-relieving tincture), the original Korean pipeline specifies '통증치료제' (pain treatment drug/analgesic).
Beyond the preview
Go deeper on ATB1091.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATB1091.